These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 37730276)

  • 1. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification and overall survival prediction in extensive stage small cell lung cancer after chemotherapy with immunotherapy based on CT radiomics.
    Wang F; Chen W; Chen F; Lu J; Xu Y; Fang M; Jiang H
    Sci Rep; 2024 Sep; 14(1):22659. PubMed ID: 39349536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
    Agarwal M; Liu A; Almquist D; Langlais BT; Leventakos K; Yu NY; Manochakian R; Ernani V
    Cancer; 2023 Nov; 129(22):3546-3553. PubMed ID: 37548029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of neutrophil-to-lymphocyte ratio in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real-world study.
    Bi H; Ren D; Xiao Y; Zhou Y; Yi B; Han W; Shao Y; Wang J; Zhang C; Wang H
    Thorac Cancer; 2024 Mar; 15(7):559-569. PubMed ID: 38294282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
    Agarwal M; Liu A; Langlais BT; Leventakos K; Yu NY; Almquist D; Manochakian R; Ernani V
    Clin Lung Cancer; 2023 Nov; 24(7):591-597. PubMed ID: 37365076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of CT radiomic features combined with clinical factors in predicting prognosis in patients with limited-stage small cell lung cancer.
    Wu J; Zhou Y; Xu C; Yang C; Liu B; Zhao L; Song J; Wang W; Yang Y; Liu N
    BMC Cancer; 2024 Feb; 24(1):170. PubMed ID: 38310283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study.
    Sun M; Ji H; Deng F; Li J; Xu N; Li Y
    BMC Cancer; 2024 Sep; 24(1):1206. PubMed ID: 39350057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
    Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
    JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics.
    Zhou Y; Wu Z; Wang H; Zhang K; Chen H; Zhu S; Sitrakiniaina A; Wu Y; Yang S; Sun X; Li W; Lin X; Jin J
    Eur J Med Res; 2024 Aug; 29(1):401. PubMed ID: 39095855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
    Peng J; Zhang L; Wang L; Feng H; Yao D; Meng R; Liu X; Li X; Liu N; Tan B; Huang Z; Li S; Meng X
    Radiat Oncol; 2023 Jul; 18(1):111. PubMed ID: 37403111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of baseline clinicopathological characteristics in first-line chemotherapy ± immunotherapy for extensive-stage small cell lung cancer: a retrospective cohort study.
    Wu Y; Ye J; Shao Z; Rossi A; Chen Y; Li Y; Wu S
    J Thorac Dis; 2024 Aug; 16(8):5348-5360. PubMed ID: 39268133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
    Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
    Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
    Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
    Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer.
    Jain P; Khorrami M; Gupta A; Rajiah P; Bera K; Viswanathan VS; Fu P; Dowlati A; Madabhushi A
    Front Oncol; 2021; 11():744724. PubMed ID: 34745966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy.
    Longo V; Della Corte CM; Russo A; Spinnato F; Ambrosio F; Ronga R; Marchese A; Del Giudice T; Sergi C; Casaluce F; Gilli M; Montrone M; Gristina V; Sforza V; Reale ML; Di Liello R; Servetto A; Lipari H; Longhitano C; Vizzini L; Manzo A; Cristofano A; Paolelli L; Nardone A; De Summa S; Perrone A; Bisceglia C; Derosa C; Nardone V; Viscardi G; Galetta D; Vitiello F
    Front Immunol; 2023; 14():1289434. PubMed ID: 38304255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy.
    Herranz-Bayo E; Chara-Velarde LE; Cassinello-Espinosa J; Gimeno-Ballester V; Artal-Cortés Á; Moratiel-Pellitero A; Alcácera-López A; Navarro-Expósito F; Riesco-Montes B; Clemente-Andujar M
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39240302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
    BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.